• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Aptar Pharma banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Regulatory

PMCPA reprimands Chiesi for misleading claims about Fostair

The UK's Prescription Medicines Code of Practice Authority (PMCPA) has reprimanded Chiesi for a misleading and unsubstantiated claim regarding the company's Fostair beclometasone/formoterol inhaler. The authority has published advertisements in the BMJ, The Pharmaceutical Journal, and The Nursing Standard that say, "The Code of Practice Panel reported the company to … [Read more...] about PMCPA reprimands Chiesi for misleading claims about Fostair

Insmed confirms filing of MAA for Arikayce, announces new hires

In its announcement of fourth quarter and full year financial results for 2014, Insmed has confirmed that it filed an MAA for Arikayce liposomal amikacin inhalation solution. The company said that the EMA's Pediatric Committee has approved the Pediatric Investigation Plan for the product, and the MAA has subsequently been validated. Insmed also announced the … [Read more...] about Insmed confirms filing of MAA for Arikayce, announces new hires

TGA warns of smoking devices that look nearly identical to MDIs

Australia's Therapeutic Goods Administration (TGA) has issued a warning about devices marketed by a company called Discreet Vape that look nearly identical to metered dose inhalers used for rescue medications for asthma. The PUFFiT and PUFFiT-X devices are advertised as "the discreet choice" for smoking "dry herbal blends." Discreet Vape, based in Hong Kong, … [Read more...] about TGA warns of smoking devices that look nearly identical to MDIs

Meda’s Dymista gets FDA approval for children aged 6-11

The FDA has approved Meda's Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of seasonal allergic rhinitis in children aged 6-11 "who require treatment with both components," the company said. Dymista was approved for adults and for children 12 and older in 2012. Meda submitted data from two pediatric trials to support the … [Read more...] about Meda’s Dymista gets FDA approval for children aged 6-11

Adapt Pharma gets Fast Track designation for intranasal naloxone

The FDA has granted Adapt Pharma Fast Track designation for its intranasal naloxone for the treatment of opioid overdose, the company said. Adapt Pharma licensed the product from Lightlake Therapeutics in December 2014. In the same month, Lightlake began a new trial of the drug for the opiod overdose reversal indication. Funding for the trial has been provided by the … [Read more...] about Adapt Pharma gets Fast Track designation for intranasal naloxone

FDA advisory committees to review Breo Ellipta sNDA (updated)

Theravance has announced that the the FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) and Drug Safety and Risk Management Advisory Committee will meet jointly on March 19, 2015 to discuss whether the Breo Ellipta fluticasone/vilanterol DPI should be approved for the treatment of asthma in patients 12 and older. Theravance and GSK filed sNDA 204275-S001 in … [Read more...] about FDA advisory committees to review Breo Ellipta sNDA (updated)

Orphan Drug Designation for AIT’s nitric oxide product for CF

Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT) has announced that it received Orphan Drug Designation from the FDA last fall for its AIT-CF high dose nitric oxide formulation for the treatment of lung infections in cystic fibrosis patients. The company says that its proprietary delivery system for the 160 ppm formulation "continuously monitors … [Read more...] about Orphan Drug Designation for AIT’s nitric oxide product for CF

PARI’s eRapid nebulizer now approved for delivery of Pulmozyme in US

PARI has announced that following approval by the FDA, its eRapid nebulizer is now available for delivery of Pulmozyme dornase alfa inhalation solution for the treatment of cystic fibrosis. In Europe, the device, marketed as eFlow Rapid, has been available for use with Pulmozyme for years. The eRapid nebulizer cuts Pulmozyme delivery time to 2-3 minutes compared … [Read more...] about PARI’s eRapid nebulizer now approved for delivery of Pulmozyme in US

Novartis announces NDA submissions for QVA149 and NVA237 DPIs

Novartis has announced that it submitted New Drug Applications to the FDA for both the QVA149 indacaterol/glycopyrronium bromide and NVA237 glycopyrronium bromide DPIs in the fourth quarter of 2014. Both inhalers are meant for the treatment of COPD. In early 2012, the company said that it planned to submit marketing applications for the two products in the US by the … [Read more...] about Novartis announces NDA submissions for QVA149 and NVA237 DPIs

Plumestars gets orphan drug designation for amikacin DPI

Italian startup Plumestars has announced via Twitter that it has received orphan drug status from the EMA for its amikacin dry powder inhaler for the treatment of P. aeruginosa infections in cystic fibrosis patients. https://twitter.com/PlumeStars/status/546688438003826688 According to the company's website, it is also developing a tobramycin DPI. … [Read more...] about Plumestars gets orphan drug designation for amikacin DPI

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 67
  • Page 68
  • Page 69
  • Page 70
  • Page 71
  • Interim pages omitted …
  • Page 99
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews